קפציטבין טבע  150 מג ישראל - עברית - Ministry of Health

קפציטבין טבע 150 מג

abic marketing ltd, israel - capecitabine - טבליות מצופות פילם - capecitabine 150 mg - capecitabine

קפציטבין טבע  500 מג ישראל - עברית - Ministry of Health

קפציטבין טבע 500 מג

abic marketing ltd, israel - capecitabine - טבליות מצופות פילם - capecitabine 500 mg - capecitabine

קפסיטבין תרו 500 מג ישראל - עברית - Ministry of Health

קפסיטבין תרו 500 מג

taro international ltd, israel - capecitabine - טבליות מצופות פילם - capecitabine 500 mg - capecitabine

קפסיטבין אינובמד 500 מג ישראל - עברית - Ministry of Health

קפסיטבין אינובמד 500 מג

inovamed ltd - capecitabine - טבליות מצופות פילם - capecitabine 500 mg - capecitabine

קפסיטבין אינובמד 500 מג ישראל - עברית - Ministry of Health

קפסיטבין אינובמד 500 מג

inovamed ltd - capecitabine - טבליות מצופות פילם - capecitabine 500 mg - capecitabine

קסלודה 150 מ"ג ישראל - עברית - Ministry of Health

קסלודה 150 מ"ג

roche pharmaceuticals (israel) ltd - capecitabine 150 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

קסלודה 500 מ"ג ישראל - עברית - Ministry of Health

קסלודה 500 מ"ג

roche pharmaceuticals (israel) ltd - capecitabine 500 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

טייקרב ישראל - עברית - Ministry of Health

טייקרב

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

איקסמפרה 15 מ"ג ישראל - עברית - Ministry of Health

איקסמפרה 15 מ"ג

bristol-myers squibb (israel) limited - ixabepilone 15 mg - powder for concentrate for infusion - ixabepilone - ixempra is indicated for the treatment of inoperable locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy:in combination with capecitabine in patients failing prior therapy with a taxane and an anthracycline or for whom further anthracycline therapy is not indicated.as monotherapy in patients failing prior therapy with taxanes, capecitabine and anthracyclines or for whom futher anthracycline therapy is not indicated.

איקסמפרה 45 מ"ג ישראל - עברית - Ministry of Health

איקסמפרה 45 מ"ג

bristol-myers squibb (israel) limited - ixabepilone 45 mg - powder for concentrate for infusion - ixabepilone - ixempra is indicated for the treatment of inoperable locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy:in combination with capecitabine in patients failing prior therapy with a taxane and an anthracycline or for whom further anthracycline therapy is not indicated.as monotherapy in patients failing prior therapy with taxanes, capecitabine and anthracyclines or for whom further anthracycline therapy is not indicated.